|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||77.13|
|Earnings date||01 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late. Horizon Therapeutics Public (NASDAQ: HZNP), a healthcare business that makes medicines to treat autoimmune and inflammatory diseases, issued a press release on Nov. 29 stating that it is in "preliminary discussions" regarding a potential acquisition of its business.